Work

A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.6_suppl.tps266

Authors: David Johnson Einstein, Atish Dipankar Choudhury, Philip James Saylor, Lillian Werner, Mark G. Erlander, Maya Ridinger, Glenn Bubley

Institutions: Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Massachusetts General Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2921425242

Cites:

Cited by: 5

Related to: 10